To improve the efficacy, a combination of F5 CAR-T with PD-1/PD-L1 inhibitors might have a synergistic effect since immune checkpoint blockade could block PD-1 and PD-L1 signal activation, allowing CAR-T cells to kill cancer cells. Here, CD274 is linked to cancer.